Who is sponsoring NCT03248336?

NCT03248336 is sponsored by Salus University.

What drugs are being tested in NCT03248336?

Interventions in NCT03248336: office-based vergence/accommodative therapy.

What condition does NCT03248336 study?

NCT03248336 studies Convergence Insufficiency.

Is NCT03248336 still recruiting?

NCT03248336 is currently status unknown. Last updated 23 October 2020.

Last reviewed 2020-10-23 · How we verify

NCT03248336

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Objective Assessment of Disparity Vergence After Treatment of Symptomatic CI in Children

Status unknown NA Last updated 23 October 2020

What this trial tests

NA trial testing office-based vergence/accommodative therapy in Convergence Insufficiency in 60 participants. Status unknown.

Timeline

2 September 2018

Primary endpoint
1 September 2022

1 December 2022

Quick facts

Lead sponsor	Salus University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	2 September 2018
Primary completion	1 September 2022
Estimated completion	1 December 2022
Sites	1 location across United States

Drugs / interventions tested

office-based vergence/accommodative therapy

Conditions studied

Convergence Insufficiency — all drugs for Convergence Insufficiency →

Sponsor

Salus University

Who can join

Adults 9 to 17, any sex, with Convergence Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate changes in objective measures of disparity vergence after office-based vergence/accommodative therapy (OBVAT) for convergence insufficiency (CI) in children 12-17 years old.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Objective Assessment of Disparity Vergence after Treatment of Symptomatic Convergence Insufficiency in Children.
Scheiman M, Talasan H, Alvarez TL. · · 2019 · cited 19× · PMID 30570596 · DOI 10.1097/opx.0000000000001320
Changes in the Disparity Vergence Main Sequence after Treatment of Symptomatic Convergence Insufficiency in Children.
Scheiman M, Yaramothu C, Alvarez TL. · · 2019 · cited 4× · PMID 32190204 · DOI 10.16910/jemr.12.4.6
Negative Fusional Vergence Is Abnormal in Children with Symptomatic Convergence Insufficiency.
Scheiman MM, Alvarez TL, Cotter SA, Kulp MT, et al · · 2021 · cited 1× · PMID 33394929 · DOI 10.1097/opx.0000000000001626

Verify or expand the search:

Other recruiting trials for Convergence Insufficiency

Currently open trials in the same condition.

NCT06886737 — Home-based Vision Therapy · Phase 1 · recruiting
NCT06913829 — Efficacy Of Pencil Pushup Exercise Vs Base Out Exercising Prism's In Patient With Convergence Insufficiency · NA · active not recruiting
NCT05877560 — Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency · NA · recruiting
NCT06105892 — Eye Recovery Automation for Post Injury Dysfunction (iRAPID) · NA · recruiting

Other Salus University trials

Trials by the same sponsor.

NCT06848673 — Natural History of MTBI-related Convergence Insufficiency & Effectiveness of Vision Therapy for MTBI-related CI · Phase 2 · not yet recruiting
NCT07282691 — Validation of Clinical Outcome Measures Specific to mTBI-Related Oculomotor Disorders · recruiting
NCT05825248 — Comparing Two Protocols to Improve Reflex Integration and Functional Performance · NA · unknown
NCT05242575 — The Influence of Immersive Virtual Field Trips on Academic Vocabulary · NA · completed
NCT04185324 — Efficacy of an Intervention to Teach Zippering: A Two-Group Control Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03248336 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Salus University
Last refreshed: 23 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03248336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing